Skip to main content
Key Specialties
Cardiology Diabetology Endocrinology Gastroenterology Geriatrics and Gerontology Gynecology and Obstetrics Hematology Infectious Disease Internal Medicine Nephrology Neurology Oncology Pediatrics Respiratory Medicine Rheumatology Surgery
Congress Coverage
2024 ACC Congress 2023 ESMO Congress 2023 EASD Congress 2023 ERS Congress 2023 ESC Congress 2023 EHA Congress 2023 ASCO Annual Meeting
Clinical Collections
Advances in Alzheimer’s

Keynote webinar | Spotlight on sleep in brain health

LIVE: Thursday 2nd May 2024, 18:00-19:30 (CEST)

Quality sleep is essential for health. But what happens to our brains when sleep patterns are disturbed? Join our experts to explore the interplay between sleep disruption and neurological diseases, and the questions that you need to be asking your patients to help you prevent the harmful effects of sleep deprivation.
ADVANCED SEARCH
Log in
Top
Breast Cancer
Published in: Breast Cancer 1/2017

01-01-2017 | Review Article

Overview on cardiac, pulmonary and cutaneous toxicity in patients treated with adjuvant radiotherapy for breast cancer

Authors: Icro Meattini, Marina Guenzi, Alessandra Fozza, Cristiana Vidali, Paolo Rovea, Fiammetta Meacci, Lorenzo Livi

Published in: Breast Cancer | Issue 1/2017

Login to get access

Abstract

Conservative management of breast cancer represents the standard treatment for early disease. Breast conserving surgery associated with radiotherapy for stage I-II has been proven to be as equally effective as mastectomy in term of local control, distant disease, and overall survival. The growing minimal invasive surgical approach on the axillary region, and the new breast reconstructive techniques, will probably lead to a significant decrease of the rate of side-effects related to mastectomy. Therefore, the adverse events caused by adjuvant radiation still remain a challenge. Cutaneous, pulmonary and cardiac toxicity represent the main toxicities of adjuvant radiotherapy for breast cancer. Safety profile of radiation is strongly dependent on the multidisciplinary management of the single case (systemic treatment, endocrine therapy, surgery), individual characteristics (i.e., co-morbidities, age, habits), and radiation-related aspects. Radiation techniques development, and facilities implementation concerning organs-at-risk sparing systems (i.e., image-guided radiotherapy, tracking systems, respiratory gating), represent brand new tools for the clinical oncologist, that would certainly minimize toxicity profile in the next future. However, data reported from published literature will greatly help physicians, to give to the patients appropriate counseling regarding the efficacy and potential adverse events of treatments, thus optimizing the informed decision-making process.
Literature
1.
Veronesi U, Salvadori B, Luini A, et al. Breast conservation is a safe method in patients with small cancer of the breast. Long-term results of three randomised trials on 1973 patients. Eur J Cancer. 1995;1995(31A):1574–9.CrossRef
2.
Fisher B, Anderson S, Bryant J, et al. Twenty-year follow-up of a randomized trial comparing total mastectomy, lumpectomy, and lumpectomy plus irradiation for the treatment of invasive breast cancer. N Engl J Med. 2002;347:1233–41.CrossRefPubMed
3.
vanDongen JA, Voogd AC, Fentiman IS. J Natl Cancer Inst. Long-term results of a randomized trial comparing breast-conserving therapy with mastectomy: European Organization for Research and Treatment of Cancer 10801 trial. 2000;92:1143–50.
4.
Early Breast Cancer Trialists’ Collaborative Group. Effects of radiotherapy and of differences in the extent of surgery for early breast cancer on local recurrence and on 15-year survival: an overview of the randomised trials. Lancet. 2005;366:2087–106.CrossRef
5.
Early Breast Cancer Trialists’ Collaborative Group. Effect of radiotherapy after breast-conserving surgery on 10-year recurrence and 15-year breast cancer death: meta-analysis of individual patient data for 10,801 women in 17 randomised trials. Lancet. 2011;378:1707–16.CrossRef
6.
Poortmans PM, Collette S, Kirkove C, et al. Internal mammary and medial supraclavicular irradiation in breast cancer. N Engl J Med. 2015;373:317–27.CrossRefPubMed
7.
8.
Darby S, Cutter D, Boerma M, et al. Radiation-related heart disease: current knowledge and future prospects. Int J Radiat Oncol Biol Phys. 2010;76:656–65.CrossRefPubMedPubMedCentral
9.
Feng M, Moran JM, Koelling T, et al. Development and validation of a heart atlas to study cardiac exposure to radiation following treatment for breast cancer. Int J Radiat Oncol Biol Phys. 2011;79:10–8.CrossRefPubMed
10.
Darby SC, McGale P, Taylor CW, et al. Long-term mortality from heart disease and lung cancer after radiotherapy for early breast cancer: prospective cohort study of about 300 000 women in US SEER cancer registries. Lancet Oncol. 2005;6:557–65.CrossRefPubMed
11.
Hooning MJ, Aleman BMP, van Rosmalen AJM, et al. Cause-specific mortality in long-term survivors of breast cancer: a 25-year follow-up study. Int J Radiat Oncol Biol Phys. 2006;64:1081–91.CrossRefPubMed
12.
Gagliardi G, Constine LS, Vitali M, et al. Radiation dose-volume effects in the heart. Int J Radiat Oncol Biol Phys. 2010;76(Suppl):S77–85.CrossRefPubMed
13.
Taylor CW, McGale P, Povall JM, et al. Estimating cardiac exposure from breast cancer radiotherapy in clinical practice. Int J Radiat Oncol Biol Phys. 2009;73:1061–8.CrossRefPubMed
14.
Azizova TV, Muirhead CR, Moseeva MB, et al. Ischemic heart disease in nuclear workers first employed at the Mayak PA in 1948–1972. Health Phys. 2012;103:3–14.CrossRefPubMed
15.
Nielsen MH, Berg M, Pedersen AN, et al. Delineation of target volumes and organs at risk in adjuvant radiotherapy of early breast cancer: national guidelines and contouring atlas by the Danish Breast Cancer Cooperative Group. Acta Oncol. 2013;52:703–10.CrossRefPubMed
16.
Haviland JS, Owen JR, Dewar JA, et al. The UK Standardisation of Breast Radiotherapy (START) trials of radiotherapy hypofractionation for treatment of early breast cancer: 10-year follow-up results of two randomised controlled trials. Lancet Oncol. 2013;14:1086–94.CrossRefPubMed
17.
Appelt AL, Vogelius IR, Bentzen SM, et al. Modern hypofractionation schedules for tangential whole breast irradiation decrease the fraction size-corrected dose to the heart. Clin Oncol (R Coll Radiol). 2013;25:147–52.CrossRef
18.
Nichols M, Townsend N, Luengo-Fernandez R, Leal J, Gray A, Scarborough P, Rayner M. European cardiovascular disease statistics 2012. Brussels: European Heart Network, European Society of Cardiology, Sophia Antipolis; 2012.
19.
Roychoudhuri R, RobinsonD Putcha V, et al. Increased cardiovascular mortality more than fifteen years after radiotherapy for breast cancer: a population-based study. BMC Cancer. 2007;7:9.CrossRefPubMedPubMedCentral
20.
Pezner RD. Coronary artery disease and breast radiation therapy. Int J Radiat Oncol Biol Phys. 2013;86:816–8.CrossRefPubMed
21.
Formenti SC, DeWyngaert JK, Jozsef G, et al. Prone vs. supine positioning for breast cancer radiotherapy. JAMA. 2012;308:861–3.CrossRefPubMed
22.
Kirby AM, Evans PM, Donovan EM, et al. Prone versus supine positioning for whole and partial-breast radiotherapy: a comparison of non-target tissue dosimetry. Radiother Oncol. 2010;96:178–84.CrossRefPubMed
23.
Mast ME, van Kempen-Harteveld L, Heijenbrok MW, et al. Left-sided breast cancer radiotherapy with and without breath-hold: does IMRT reduce the cardiac dose even further? Radiother Oncol. 2013;108:248–53.CrossRefPubMed
24.
Halyard MY, Pisansky TM, Dueck AC, et al. Radiotherapy and adjuvant trastuzumab in operable breast cancer: tolerability and adverse event data from the NCCTG Phase III Trial N9831. J Clin Oncol. 2009;27:2638–44.CrossRefPubMedPubMedCentral
25.
Belkacémi Y, Gligorov J, Ozsahin M, et al. Concurrent trastuzumab with adjuvant radiotherapy in HER2-positive breast cancer patients: acute toxicity analyses from the French multicentric study. Ann Oncol. 2008;19:1110–6.CrossRefPubMed
26.
Meattini I, Cecchini S, Muntoni C, et al. Cutaneous and cardiac toxicity of concurrent trastuzumab and adjuvant breast radiotherapy: a single institution series. Med Oncol. 2014;31:891.CrossRefPubMed
27.
Patt DA, Goodwin JS, Kuo YF, et al. Cardiac morbidity of adjuvant radiotherapy for breast cancer. J Clin Oncol. 2005;23:7475–82.CrossRefPubMed
28.
29.
Harris EE, Correa C, Hwang WT, et al. Late cardiac mortality and morbidity in early-stage breast cancer patients after breast-conservation treatment. J Clin Oncol. 2006;24:4100–6.CrossRefPubMed
30.
Darby SC, Ewertz M, McGale P, et al. Risk of ischemic heart disease in women after radiotherapy for breast cancer. N Engl J Med. 2013;368:987–98.CrossRefPubMed
31.
Marks LB, Yu X, Vujaskovic Z, et al. Radiation-induced lung injury. sem. Radiat Oncol. 2003;13:333–45.CrossRef
32.
Abid S, Malhotra V, Perry M, et al. Radiation-induced and chemotherapy-induced pulmonary injury. Curr Opin Oncol. 2001;13:242–8.CrossRefPubMed
33.
Rubin P, Finkelstein JN, Shapiro D, et al. Molecular biology mechanisms in the radiation induction of pulmonary injury syndromes: interrelationship between the alveolar macrophage and the septal fibroblast. Int J Radiat Oncol Biol Phys. 1992;24:93–101.CrossRefPubMed
34.
Rubin P, Johnston CJ, Williams JP, et al. A perpetual cascade of cytokines post irradiation leads to pulmonary fibrosis. Int J Radiat Oncol Biol Phys. 1995;33:99–109.CrossRefPubMed
35.
Vujaskovic Z, Marks LB, Anscher MS. The physical parameters and molecular events associated with radiation-induced lung toxicity. Semin Radiat Oncol. 2000;4:296–307.CrossRef
36.
Haston CK, Zhou X, Gumbiner-Russo L, et al. Universal and radiation-specific loci influence murine susceptibility to radiation-induced pulmonary fibrosis. Cancer Res. 2002;62:3782–8.PubMed
37.
Vujaskovic Z, Anscher MS, Feng QF, et al. Radiationinduced hypoxia may perpetuate late normal tissue injury. Int J Radiat Oncol Biol Phys. 2001;50:851–5.CrossRefPubMed
38.
Woel RT, Munley MT, Hollis D, et al. The time course of radiation therapy-induced reductions in regional perfusion: a prospective study with 5 years of follow-up. Int J Radiat Oncol Biol Phys. 2002;52:58–67.CrossRefPubMed
39.
Smith LM, Mendenhall NP, Cicale MJ, et al. Results of prospective study evaluating the effects of mantle irradiation on pulmonary function. Int J Radiat Oncol Biol Phys. 1989;16:79–84.CrossRefPubMed
40.
Sunyach M, Falchero L, Pommier P, et al. Prospective evaluation of early lung toxicity following three-dimensional conformal radiation therapy in non-small-cell lung cancer: preliminary results. Int J Radiat Oncol Biol Phys. 2000;48:459–63.CrossRefPubMed
41.
Epler GR. Post-breast cancer radiotherapy bronchiolitis obliterans organizing pneumonia. Expert Rev Respir Med. 2013;7:109–12.CrossRefPubMed
42.
Lind PA, Wennberg B, Gagliardi G, et al. Pulmonary complications following different radiotherapy techniques for breast cancer, and the association to irradiated lung volume and dose. Breast Cancer Res Treat. 2001;68:199–210.CrossRefPubMed
43.
Holli K, Pitkänen M, Järvenpää R, et al. Early skin and lung reactions in breast cancer patients after radiotherapy: prospective study. Radiother Oncol. 2002;64:163–9.CrossRefPubMed
44.
Gagliardi G, Bjohle J, Lax I, et al. Radiation pneumonitis after breast cancer irradiation: analysis of the complication probability using the relative seriality model. Int J Radiat Oncol Biol Phys. 2000;46:373–81.CrossRefPubMed
45.
Kahán Z, Csenki M, Varga Z, et al. The risk of early and late lung sequelae after conformal radiotherapy in breast cancer patients. Int J Radiat Oncol Phys. 2007;68:673–81.CrossRef
46.
Kubo A, Osaki K, Kawanaka T, et al. Risk factors for radiation pneumonitis caused by whole breast irradiation following breast-conserving surgery. J Med Invest. 2009;56:99–110.CrossRefPubMed
47.
Blom Goldman U, Wennberg B, Svane G, et al. Radiat Oncol. Reduction of radiation pneumonitis by V20-constraints in breast cancer. 2010;5:99.
48.
Rancati T, Wennberg B, Lind P, et al. Early clinical and radiological pulmonary complications following breast cancer radiation therapy: nTCP fit with four different models. Radiother Oncol. 2007;82:308–16.CrossRefPubMed
49.
Yarnold J, Bentzen SM, Coles C, et al. Hypofractionated whole-breast radiotherapy for women with early breast cancer: myths and realities. Int J Radiat Oncol Biol Phys. 2011;79:1–9.CrossRefPubMed
50.
Koc M, Polat P, Suma S. Effects of tamoxifen on pulmonary fibrosis after cobalt-60 radiotherapy in breast cancer patients. Radiother Oncol. 2002;64:171–5.CrossRefPubMed
51.
Azria D, Larbouret C, Cunat S, et al. Letrozole sensitizes breast cancer cells to ionizing radiation. Breast Cancer Res. 2005;7:R156–63.CrossRefPubMed
52.
Varga Z, Cserhati A, Kelemen G, et al. Role of systemic therapy in the development of lung sequelae after conformal radiotherapy in breast cancer patients. Int J Radiat Oncol Biol Phys. 2011;80:1109–16.CrossRefPubMed
53.
Henson KE, McGale P, Taylor C, et al. Radiation-related mortality from heart disease and lung cancer more than 20 years after radiotherapy for breast cancer. Br J Cancer. 2013;108:179–82.CrossRefPubMed
54.
Murphy C, Anderson PR, Li T, et al. Impact of the radiation boost on outcomes after breast-conserving surgery and radiation. Int J Radiat Oncol Biol Phys. 2011;81:69–76.CrossRefPubMed
55.
Manning MA, Arthur DW, Schmidt-Ullrich RK, et al. Interstitial high-dose-rate brachytherapy boost: the feasibility and cosmetic outcome of a fractionated outpatient delivery scheme. Int J Radiat Oncol Biol Phys. 2000;48:1301–6.CrossRefPubMed
56.
Whelan TJ, Pignol JP, Levine MN, et al. Long-term results of hypofractionated radiation therapy for breast cancer. N Engl J Med. 2010;362:513–20.CrossRefPubMed
57.
Romestaing P, Lehingue Y, Carrie C, et al. Role of a 10-Gy boost in the conservative treatment of early breast cancer: results of a randomized clinical trial in Lyon. France. J Clin Oncol. 1997;15:963–8.PubMed
58.
Polgár C, Major T, Fodor J, et al. High-dose-rate brachytherapy alone versus whole breast radiotherapy with or without tumor bed boost after breast-conserving surgery: seven-year results of a comparative study. Int J Radiat Oncol Biol Phys. 2004;60:1173–81.CrossRefPubMed
59.
Sacchini V, Luini A, Agresti R, et al. The influence of radiotherapy on cosmetic outcome after breast conservative surgery. Int J Radiat Oncol Biol Phys. 1995;33:59–64.CrossRefPubMed
60.
Deutsch M, Flickinger JC. Patient characteristics and treatment factors affecting cosmesis following lumpectomy and breast irradiation. Am J Clin Oncol. 2003;26:350–3.PubMed
61.
Fehlauer F, Tribius S, Alberti W, et al. Late effects and cosmetic results of conventional versus hypofractionated irradiation in breast-conserving therapy. Strahlenther Onkol. 2005;181:625–31.CrossRefPubMed
62.
Bartelink H, Maingon P, Poortmans P, et al. Whole-breast irradiation with or without boost for patients treated with breast-conserving surgery for early breast cancer: 20-year follow-up of a randomised phase 3 trial. Lancet Oncol. 2015;16:47–56.CrossRefPubMed
63.
Poortmans PM, Collette L, Horiot JC, et al. Impact of the boost dose of 10 Gy versus 26 Gy in patients with early stage breast cancer after a microscopically incomplete lumpectomy: 10-year results of the randomised EORTC boost trial. Radiother Oncol. 2009;90:80–5.CrossRefPubMed
64.
Johansson B, Karlsson L, Liljegren G, et al. Pulsed dose rate brachytherapy as the sole adjuvant radiotherapy after breast-conserving surgery of T1-T2 breast cancer: first long time results from a clinical study. Radiother Oncol. 2009;90:30–5.CrossRefPubMed
65.
Ott OJ, Hildebrandt G, Pötter R, et al. Accelerated partial breast irradiation with multi-catheter brachytherapy: local control, side effects and cosmetic outcome for 274 patients. Results of the German-Austrian multi-centre trial. Radiother Oncol. 2007;82:281–6.CrossRefPubMed
66.
Bellon JR, Lindsley KL, Ellis GK, et al. Concurrent radiation therapy and paclitaxel or docetaxel chemotherapy in high-risk breast cancer. Int J Radiat Oncol Biol Phys. 2000;48:393–7.CrossRefPubMed
67.
Wazer DE, Kaufman S, Cuttino L, et al. Accelerated partial breast irradiation: an analysis of variables associated with late toxicity and long-term cosmetic outcome after high-dose-rate interstitial brachytherapy. Int J Radiat Oncol Biol Phys. 2006;64:489–95.CrossRefPubMed
68.
Toledano AH, Bollet MA, Fourquet A, et al. Does concurrent radiochemotherapy affect cosmetic results in the adjuvant setting after breast-conserving surgery? results of the ARCOSEIN multicenter, phase III study: patients’ and doctors’ views. Int J Radiat Oncol Biol Phys. 2007;68:66–72.CrossRefPubMed
69.
Waljee JF, Hu ES, Ubel PA, et al. Effect of esthetic outcome after breast-conserving surgery on psychosocial functioning and quality of life. J Clin Oncol. 2008;20:3331–7.CrossRef
70.
Rubin P, Constine LS, Fajardo LF, RTOG Late Effects Working Group, et al. Overview Late effects of normal tissues (LENT) scoring system. Int J Radiat Oncol Biol Phys. 1995;31:1041–2.CrossRefPubMed
71.
Pavy JJ, Denekamp J, Letschert J, EORTC Late Effects Working Group, et al. Late effects toxicity scoring: the SOMA scale. Int J Radiat Oncol Biol Phys. 1995;31:1043–7.CrossRefPubMed
72.
Cox JD, Stetz J, Pajak TF, et al. Toxicity criteria of the Radiation Therapy Oncology Group (RTOG) and the European Organization for Research and Treatment of Cancer (EORTC). Int J Radiat Oncol Biol Phys. 1995;31:1341–6.CrossRefPubMed
73.
Harris JR, Levene MB, Svensson G, et al. Analysis of cosmetic results following primary radiation therapy for stages I and II carcinoma of the breast. Int J Radiat Oncol Biol Phys. 1979;5:257–61.CrossRefPubMed
74.
Bentzen SM, Agrawal RK, Aird EG, et al. The UK Standardisation of Breast Radiotherapy (START) Trial A of radiotherapy hypofractionation for treatment of early breast cancer: a randomised trial. Lancet Oncol. 2008;9:331–41.CrossRefPubMed
75.
Bentzen SM, Agrawal RK, Aird EG, et al. The UK Standardisation of Breast Radiotherapy (START) trial B of radiotherapy hypofractionation for treatment of early breast cancer: a randomised trial. Lancet. 2008;371:1098–107.CrossRefPubMed
76.
Collette S, Collette L, Budiharto T, et al. Predictors of the risk of fibrosis at 10 years after breast conserving therapy for early breast cancer: a study based on the EORTC Trial 22881-10882 ‘boost versus no boost’. Eur J Cancer. 2008;44:2587–99.CrossRefPubMed
77.
Livi L, Meattini I, Marrazzo L, et al. Accelerated partial breast irradiation using intensity-modulated radiotherapy versus whole breast irradiation: 5-year survival analysis of a phase 3 randomised controlled trial. Eur J Cancer. 2015;51:451–63.CrossRefPubMed
78.
Jagsi R, Ben-David MA, Moran JM, et al. Unacceptable cosmesis in a protocol investigating intensity-modulated radiotherapy with active breathing control for accelerated partial-breast irradiation. Int J Radiat Oncol Biol Phys. 2010;76:71–8.CrossRefPubMedPubMedCentral
79.
Olivotto IA, Whelan TJ, Parpia S, et al. Interim cosmetic and toxicity results from RAPID: a randomized trial of accelerated partial breast irradiation using three-dimensional conformal external beam radiation therapy. J Clin Oncol. 2013;31:4038–45.CrossRefPubMed
80.
Yarnold J, Bentzen SM, Coles C, et al. Hypofractionated whole-breast radiotherapy for women with early breast cancer: myths and realities. Int J Radiat Oncol Biol Phys. 2011;79:1–9.CrossRefPubMed
81.
Chargari C, Toillon RA, MacDermed D, et al. Concurrent hormone and radiation therapy in patients with breast cancer: what is the rationale? Lancet Oncol. 2009;10:53–60.CrossRefPubMed
82.
83.
Livi L, Meattini I, Scotti V, et al. Concomitant adjuvant chemo-radiation therapy with anthracycline-based regimens in breast cancer: a single centre experience. Radiol Med. 2011;116:1050–8.CrossRefPubMed
84.
Hanna YM, Baglan KL, Stromberg JS, et al. Acute and subacute toxicity associated with concurrent adjuvant radiation therapy and paclitaxel in primary breast cancer therapy. Breast J. 2002;8:149–53.CrossRefPubMed
85.
Toledano A, Azria D, Garaud P, et al. Phase III trial of concurrent or sequential adjuvant chemoradiotherapy after conservative surgery for early-stage breast cancer: final results of the ARCOSEIN trial. J Clin Oncol. 2007;25:405–10.CrossRefPubMed
86.
Chawla AK, Kachnic LA, Taghian AG, et al. Radiotherapy and breast reconstruction: complications and cosmesis with TRAM versus tissue expander/implant. Int J Radiat Oncol Biol Phys. 2002;54:520–6.CrossRefPubMed
87.
Albornoz CR, Matros E, McCarthy CM, et al. Implant breast reconstruction and radiation: a multicenter analysis of long-term health-related quality of life and satisfaction. Ann Surg Oncol. 2014;21:2159–64.CrossRefPubMed
88.
Emami B, Lyman J, Brown A, et al. Tolerance of normal tissue to therapeutic irradiation. Int J Radiat Oncol Biol Phys. 1991;21:109–22.CrossRefPubMed
89.
Marks LB, Yorke ED, Jackson A, et al. Use of normal tissue complication probability models in the clinic. Int J Radiat Oncol Biol Phys. 2010;76:S10–9.CrossRefPubMedPubMedCentral
90.
Bentzen SM, Constine LS, Deasy JO, et al. Quantitative analyses of normal tissue effects in the clinic (QUANTEC): an introduction to the scientific issues. Int J Radiat Oncol Biol Phys. 2010;76:S3–9.CrossRefPubMedPubMedCentral
Metadata
Title
Overview on cardiac, pulmonary and cutaneous toxicity in patients treated with adjuvant radiotherapy for breast cancer
Authors
Icro Meattini
Marina Guenzi
Alessandra Fozza
Cristiana Vidali
Paolo Rovea
Fiammetta Meacci
Lorenzo Livi
Publication date
01-01-2017
Publisher
Springer Japan
Published in
Breast Cancer / Issue 1/2017
Print ISSN: 1340-6868
Electronic ISSN: 1880-4233
DOI
https://doi.org/10.1007/s12282-016-0694-3

Other articles of this Issue 1/2017

Breast Cancer 1/2017 Go to the issue

Original Article

Efficacy and safety of leuprorelin acetate 6-month depot, TAP-144-SR (6M), in combination with tamoxifen in postoperative, premenopausal patients with hormone receptor-positive breast cancer: a phase III, randomized, open-label, parallel-group comparative study

Original Article

The roles of 18F-FDG-PET/CT and US-guided FNAC in assessment of axillary nodal metastases in breast cancer patients

Original Article

The benefit of deep inspiration breath hold: evaluating cardiac radiation exposure in patients after mastectomy and after breast-conserving surgery

Original Article

A comparison of clinicopathological characteristics and long-term survival outcomes between symptomatic and screen-detected breast cancer in Japanese women

Original Article

Efficacy and safety of re-induction therapy with bevacizumab and paclitaxel for metastatic breast cancer

Special Feature

Possible supplemental breast cancer screening modalities
Webinar | 19-02-2024 | 17:30 (CET)

Keynote webinar | Spotlight on antibody–drug conjugates in cancer

Watch now

Antibody–drug conjugates (ADCs) are novel agents that have shown promise across multiple tumor types. Explore the current landscape of ADCs in breast and lung cancer with our experts, and gain insights into the mechanism of action, key clinical trials data, existing challenges, and future directions.

Dr. Véronique Diéras
Prof. Fabrice Barlesi
Developed by: Springer Medicine
Image Credits